Table 2 Pluripotent stem cell clinical trials (USA)
Trial sponsor | Disease target | Cell therapy |
|---|---|---|
Geron Inc. Phase I: 10 patients enrolled 2010-12 | Complete subacute thoracic spinal cord injuries. T3 to T10 segments between seven and 14 days after injury | Human embryonic stem cell derived Oligodendrocyte progenitor cells (GRNOPC1) |
Advanced Cell Technologies (ACT) Phase I/II: 12 patients Enrolled 2011 | Stargardt's Macular Dystrophy (juvenile macular degeneration) | Retinal Pigment Epithelium derived from human embryonic stem cells |
Advanced Cell Technologies (ACT) Phase I/II: 12 patients Enrolled 2011-12 | Age-related Macular Degeneration | Retinal Pigment Epithelium derived from human embryonic stem cells |
California Stem Cell (CSC) Phase I Currently on hold 2011 | Spinal muscular atrophy (SMA) Type 1 | Human motor neuron progenitor cells derived from human embryonic stem cells |